Abstract
Exenatide extended release is a once-weekly injectable medication used for the treatment of type II diabetes mellitus. The long-acting formulation consists of the original twice-daily formulation encapsulated in 0.06-mm-diameter microspheres.1 The subcutaneously injected exenatide microspheres then diffuse the medication slowly over time, reaching therapeutic range by 2 weeks and steady state by 6 to 7 weeks.1 Pharmacologically, it acts as an incretin analogue that activates glucagonlike peptide 1 receptors causing a glucose-dependent insulin secretion.2 Exenatide reduces Hgb-A1C, fasting and postprandial glucose, and bodyweight.2 The most commonly reported adverse events include nausea, vomiting, diarrhea, and headache.2 Common adverse reactions at the injection site include pruritus, erythema, and subcutaneous nodules, which have reportedly resolved without intervention or limiting treatment.1, 3 These reactions are thought to be either an inflammatory foreign body reaction or an antiexenatide antibody response.1, 4 A handful of cases have also identified eosinophil-rich granulomatous panniculitis at the exenatide injection site, along with more persistent, nonresolving nodules.5, 6, 7, 8 For these rarer, persistent nodules, hospitalization and surgical intervention have been reported.8 We report a case of persistent exenatide extended release panniculitis nodules successfully treated with serial intralesional triamcinolone injections.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.